Laurent Eckert
0000-0002-7801-4125
7 papers found
Refreshing results…
Recommended core outcome instruments for health‐related quality of life, long‐term control and itch intensity in atopic eczema trials: results of the HOME VII consensus meeting
A phase 2, open-label study of single dose dupilumab in children aged 6 months to <6 years with severe uncontrolled atopic dermatitis: pharmacokinetics, safety and efficacy
Dupilumab Significantly Improves Sleep Outcomes in Adult Patients with Atopic Dermatitis: Results from Five Randomized Clinical Trials
The patient‐reported disease burden in adults with atopic dermatitis: a cross‐sectional study in Europe and Canada
Dupilumab in adolescents with uncontrolled moderate‐to‐severe atopic dermatitis: results from a phase II a open‐label trial and subsequent phase III open‐label extension
Dupilumab provides important clinical benefits to patients with atopic dermatitis who do not achieve clear or almost clear skin according to the Investigator's Global Assessment: a pooled analysis of data from two phase III trials
Burden of atopic dermatitis in Japanese adults: Analysis of data from the 2013 National Health and Wellness Survey
Missing publications? Search for publications with a matching author name.